iX Biopharma (SGX:42C) Total Stockholders Equity : S$3.51 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is iX Biopharma Total Stockholders Equity?

iX Biopharma's Total Stockholders Equity for the quarter that ended in Dec. 2024 was S$3.51 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. iX Biopharma's Book Value per Share for the quarter that ended in Dec. 2024 was S$0.00. The ratio of a company's debt over equity can be used to measure how leveraged this company is. iX Biopharma's Debt-to-Equity for the quarter that ended in Dec. 2024 was 1.40.

iX Biopharma Total Stockholders Equity Historical Data

The historical data trend for iX Biopharma's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iX Biopharma Total Stockholders Equity Chart

iX Biopharma Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Total Stockholders Equity

Get a 7-Day Free Trial

10.17

11.71

19.74

15.85

4.34

iX Biopharma Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Stockholders Equity	Get a 7-Day Free Trial															17.28	15.85	7.66	4.34	3.51

iX Biopharma (SGX:42C) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

iX Biopharma's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(3.514	-	0)	/	883.336
	=	0.00

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

iX Biopharma's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.954	+	1.969)	/	3.514
	=	1.40

iX Biopharma Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of iX Biopharma's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

iX Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » iX Biopharma Ltd (SGX:42C) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994

Website

https://www.ixbiopharma.com

iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.

iX Biopharma Headlines

No Headlines